Board approval of the 2025 Financial statements for Medistim ASA
(Oslo, 14th of April 2026) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the Board of Medistim ASA has approved the Financial Statements for 2025. The Financial Statements are without changes from the preliminary Financial Statements published on the 27th of February 2026. The annual report for 2025 is now available. The Annual General Meeting will be held on 6th of May 2025.
About Medistim: Medistim was established in 1984, and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, Canada, China, Sweden, Japan and Norway, in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, and South America. For more information, visit the Medistim home page: www.Medistim.com
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
For more information, contact: President and CEO, Kari E. Krogstad, Medistim ASA Tel: + 47 918 38 110 Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA Tel: + 47 906 59 940 Email: thomas.jakobsen@medistim.com